Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber and the Jimmy Fund assume no liability for inaccuracies that may result from using this third-party tool, which is for website translation.

Accelerating progress for adenoid cystic carcinoma

Adenoid Cystic Carcinoma Research Foundation

Fall 2023
By Kayla Carcone

Nearly two decades ago, Marnie Kaufman was diagnosed with adenoid cystic carcinoma (ACC), a rare type of cancer most commonly arising in the salivary glands. Shortly thereafter, she and her husband, Jeff, established the Adenoid Cystic Carcinoma Research Foundation (ACCRF), which has fueled ACC research and discoveries around the world ever since. Over the last year, ACCRF has awarded grants to Dana-Farber investigators totaling more than $700,000. Institute physician-scientists Maxim Pimkin, MD, PhD; Jacob Berchuck, MD; and Glenn Hanna, MD, director of the Center for Salivary and Rare Head and Neck Cancers, hope the funds will help them elucidate long-harbored questions in the areas of molecular mechanisms and oncoproteins, as well as explore new approaches to disease detection and the use of implantable microdevices.

“It is an honor to help accelerate both basic and translational ACC research at Dana-Farber.”

Jeff Kaufman, ACCRF

In particular, Pimkin’s research aims to better understand and expand what is known about the MYB family of genes, which are often aberrantly expressed in ACC and other cancers. Through funding from ACCRF, he will study the unique gene-regulatory functions of fusions occurring in MYB and MYBL1 and will work to define their molecular mechanisms through targeted protein degradation. These studies have the potential to uncover new targets for treatment, which could lead to further drug development and increased care options for more patients.

“These grants help us propel the research necessary to understand the basic mechanisms underlying ACC, which will help unlock better treatments and potentially even cures,” said Pimkin. “The generosity of ACCRF allows me and my colleagues to continue meeting our core responsibility: to advance discoveries against cancer for today’s patients and society at large.”

“At the center of our efforts is enabling cutting-edge research in oncology,” said ACCRF Executive Director Jeff Kaufman. “Twenty years ago, ACC was largely under-researched. With the partnership of the world’s leading oncology researchers, we have transformed the landscape from a backwater into a vibrant field of study. It is an honor to help accelerate both basic and translational ACC research at Dana-Farber.”

,
Copy link
Powered by Social Snap